We posted last week about the Lone Pine order entered in the Celebrex litigation, and we received a few responses to that post.
Then we saw the letter from six drug companies to FASB, about which we posted on Friday.
The combination of those two things got us to thinking.
And if we’ve bothered
We haven’t yet said a peep about the FAS 5 brouhaha.
And, Lord knows, we haven’t had to.
In a nutshell, the Financial Accounting Standards Board has proposed to amend FASB Statement No. 5 to require companies to make additional disclosures about pending “loss contingencies,” which means making more public statements about pending litigation.
For
We were pleased to see that Judge Breyer has entered a so-called “Lone Pine” order in the Celebrex multidistrict litigation. Here’s a link to the order.
Lone Pine was a New Jersey state court case in which the judge ordered plaintiffs to offer proof connecting the defendant’s product to the plaintiff’s alleged injury.
Every once in a while, you’re asked to name the mass torts.
You typically start with asbestos and breast implants, and then stammer out a few more.
But one of us is now doing some work that requires focusing specifically on the drug and device mass torts, so — cleverly combining client work with blogging
According to this article in today’s New York Times, many of the workers seeking damages for injuries allegedly sustained while working at the World Trade Center clean-up site have suffered no injury at all, or seek damages for injuries, such as a deviated septum, that couldn’t possibly be related to work at Ground Zero.
We’ll report here on one last thing that we heard at the ALI Mass Litigation conference in Charleston last month — because they are words that should be in the public domain.
A plaintiffs’ lawyer speaking at the conference said that MDL transferee judges create trouble when they appoint to the plaintiffs’ steering committee lawyers
A couple of months ago, we spied the Supreme Court case of Taylor v. Sturgell as being one to watch. In the words of the Mass Tort Litigation Blog, “[t]he D.C. Circuit had held that a plaintiff was barred by claim preclusion from pursuing his FOIA claim because he was virtually represented by an earlier
Ordinarily, a federal trial court cannot order that some other lawsuit in state court be stopped.
When federal courts preliminarily approve class action settlements, however, they often enjoin prosecution of competing cases that could interfere with the settlement. Federal courts issue those injunctions under the “in aid of jurisdiction” exception to the Anti-Injunction Act. See
One of your dynamic blogging duo — we won’t say which one — strolled down the street recently to watch, on behalf of an interested client, the opening statements in a product liability trial.
The trial court had consolidated the claims of more than two dozen plaintiffs to be decided in this one trial. (The
One panel at the Tulane MDL Symposium consisted of the triumvirate of Judges Mark Davidson, Carol Higbee, and Janis Jack.
Judge Davidson handles the Texas statewide asbestos proceedings; his was an interesting talk, but this blog doesn’t worry too much about asbestos. We learned two things of broader interest that we’ll share.
First, the chair